| HOME >> BIOLOGY >> TECHNOLOGY |
DYNEPO (epoetin delta) (trademark of Sanofi Aventis)
EPIVIR (lamivudine) (trademark of GSK)
EPZICOM (lamivudine) (trademark of GSK)
JUVISTA (trademark of Renovo)
PENTASA (mesalamine) (trademark of Ferring)
RAZADYNE (galantamine) (trademark of Johnson & Johnson)
RAZADYNE ER (galantamine) (trademark of Johnson & Johnson)
REMINYL (galantamine) (trademark of Johnson & Johnson, excluding UK and
Republic of Ireland) REMINYL XL (galantamine) (trademark of Johnson &
Johnson, excluding UK and Republic of Ireland)
SOLARAZE (diclofenac sodium (3%w/w)) (trademark of Almirall)
VANIQA (eflornithine hydrochloride) (trademark of Almirall)
ZEFFIX (lamivudine) (trademark of GSK)
Results of operations under IFRS
For the year to December 31, 2007 the Group's total revenues increased by 36% to US$2,436.3 million, compared to US$1,796.5 million in 2006. Net income for the year to December 31, 2007 was US$82.4 million compared to US$56.2 million in 2006. The results for 2007 include impairment charges in respect of goodwill and other intangible assets totaling US$390.5 million (2006: US$273.0 million) and gains on the sale of product rights of US$102.9 million (2006: US$63.0 million).
Total revenues
The following table provides an analysis of the Group's total revenues by source:
Year to December 31, 2007 2006 Change
US$M US$M %
__________ __________ ________
Product sales 2,170.2 1,535.8 +41
Royalties 247.2 242.9 +2
Other revenues 18.9 17.8 +6
__________ __________ ________
Total 2,436.3
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |